<DOC>
	<DOCNO>NCT02587117</DOCNO>
	<brief_summary>Oral lichen planus ( OLP ) common sub-acute , chronic inflammatory mucocutaneous disease.This study evaluate comparative efficacy lycopene prednisolone treatment oral lichen planus . Half participant ( total number participant twenty eight ) receive lycopene half receive prednisolone .</brief_summary>
	<brief_title>A Clinical Trial Study Effects Two Drugs , Lycopene Prednisolone Patients With Oral Lichen Planus</brief_title>
	<detailed_description>Prednisolone lycopene produce remission lesion oral lichen planus patient , different mechanism . The main cause oral lichen planus still unknown . Some author advocate disease appear result T-cell-mediated autoimmune response oral epithelial tissue . But , recent study suggest increase reactive oxygen specie ( ROS ) lipid peroxidation together imbalance antioxidant defense system may play part generation disease . Lycopene exert antioxidant activity physical chemical quench free radical decrease free radicals-initiated oxidative reaction , particularly lipid peroxidation DNA oxidative damage , thereby prevent tissue damage . Prednisone anti-inflammatory immunosuppressant effects.It suppress inflammatory response limit recruitment inflammatory cell inhibit synthesis pro-inflammatory product prostaglandin ( PGs ) , leukotrienes ( LTs ) platelet activate factor ( PAF ) indirectly inhibit phospholipase A2 negative regulating cyclooxygenase ( COX-2 ) .</detailed_description>
	<mesh_term>Lichen Planus , Oral</mesh_term>
	<mesh_term>Lichen Planus</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Lycopene</mesh_term>
	<mesh_term>Carotenoids</mesh_term>
	<criteria>Subject symptomatic i.e . burn sensation and/or pain secondary oral lichen planus . Subject clinically &amp; histopathologically diagnosed oral lichen planus . Subject treatment treatment likely modify oral lichen planus ( e.g . systemic steroid , antifungal , immunosuppressant 's , antioxidant ) . Suffering systemic disease/s diabetes , hypertension , cardiovascular , respiratory system disease , renal dysfunction , liver disorder , malignancy , active peptic ulcer disease , acute gastrointestinal disease , anemia glaucoma , etc . Suffering serious recurrent infection , immunodeficiency HIV . Pregnant breast feeding ( include woman wish pregnant study period ) . Any mucosal diseases skin disease might associate oral lesion . On drug therapy might cause lichen planus like lesion . Known allergy contraindication study medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Antioxidant</keyword>
	<keyword>Lycopene</keyword>
	<keyword>Prednisolone</keyword>
</DOC>